{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:10:42Z","timestamp":1788844242076,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>More than 90% of metastatic colorectal cancers (mCRC) are microsatellite-stable (MSS), an immunologically \u201ccold\u201d subtype characterized by low neoantigen burden, impaired antigen presentation, and poor responsiveness to immune checkpoint inhibitors (ICIs). Epigenetic aberrations\u2014including aberrant DNA methylation and histone deacetylation\u2014drive immune evasion in MSS CRC. Histone deacetylase inhibitors (HDACi) can restore major histocompatibility complex class I (MHC-I) expression, reshape the immunosuppressive tumor microenvironment (TME), and synergize with ICIs to enhance antitumor immunity. This retrospective study evaluated chidamide (a selective HDACi) plus a PD-1 inhibitor in two MSS CRC patients with prior ICI progression, with a mechanistic discussion informed by published evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>Case 1: A 60-year-old woman with BRAF V600E-mutant, right-sided, MSS mCRC received third-line surufatinib plus camrelizumab, with a best response of stable disease (SD) and a progression-free survival (PFS) of 5 months. After subsequent disease progression, fifth-line chidamide plus sintilimab achieved a partial response (PR), with a PFS of 6 months. Case 2: A 43-year-old man with recurrent RAS\/BRAF wild-type MSS mCRC received fifth-line surufatinib plus sintilimab (PR, PFS 8.5 months) and, after progression, seventh-line chidamide plus sintilimab plus bevacizumab (SD, PFS 5.5 months). No grade 3\u20134 AEs occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This retrospective two-patient case series observed one PR and one SD in heavily pretreated MSS mCRC patients with prior ICI failure who received chidamide plus a PD-1 inhibitor (Case 1: primary resistance; Case 2: acquired resistance). As descriptive observations, these findings are hypothesis-generating only and are insufficient to demonstrate reversal of immunotherapy resistance or survival benefit. Prospective biomarker-driven studies are warranted to evaluate epigenetic-immunotherapy combinations in this subgroup.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1905769","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:26:59Z","timestamp":1788841619000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical activity of chidamide-containing regimens after prior PD-1-based therapy in two patients with microsatellite-stable metastatic colorectal cancer: a case series and narrative review"],"prefix":"10.3389","volume":"16","author":[{"given":"Runzhi","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Huazhong University of Science and Technology, Tongji Medical College, Hubei Cancer Hospital","place":["Wuhan, Hubei, China"]},{"name":"Hubei Provincial Clinical Research Center for Colorectal Cancer","place":["Wuhan, Hubei, China"]},{"name":"Wuhan Clinical Research Center for Colorectal Cancer","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Huazhong University of Science and Technology, Tongji Medical College, Hubei Cancer Hospital","place":["Wuhan, Hubei, China"]},{"name":"Hubei Provincial Clinical Research Center for Colorectal Cancer","place":["Wuhan, Hubei, China"]},{"name":"Wuhan Clinical Research Center for Colorectal Cancer","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Huazhong University of Science and Technology, Tongji Medical College, Hubei Cancer Hospital","place":["Wuhan, Hubei, China"]},{"name":"Hubei Provincial Clinical Research Center for Colorectal Cancer","place":["Wuhan, Hubei, China"]},{"name":"Wuhan Clinical Research Center for Colorectal Cancer","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm023","article-title":"Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"19","author":"Van Cutsem","year":"2008","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1112276","article-title":"Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer","volume":"13","author":"Ros","year":"2023","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/nejmoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"373","author":"Diaz","year":"2015","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-3416","article-title":"Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, phase II trial","volume":"27","author":"Cousin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/jci134915","article-title":"mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","author":"Cafri","year":"2020","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.08.057","article-title":"Epigenetic orchestration of cancer-immune dynamics: mechanisms, technologies, and clinical advancements","volume":"83","author":"Lu","year":"2026","journal-title":"J Adv Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.70023","article-title":"Epi-immunotherapy in cancer treatment: mechanisms, clinical progress, and future directions","volume":"4","author":"Lu","year":"2025","journal-title":"Cancer Innov"},{"key":"B12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s43556-025-00373-5","article-title":"Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications","volume":"6","author":"Ma","year":"2025","journal-title":"Mol BioMed"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02583","article-title":"Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, O6-methylguanine-DNA methyltransferase-silenced metastatic colorectal cancer: the MAYA trial","volume":"40","author":"Morano","year":"2022","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13148-023-01485-x","article-title":"A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer","volume":"15","author":"Baretti","year":"2023","journal-title":"Clin Epigenet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02813-1","article-title":"Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41576-020-00287-8","article-title":"Active turnover of DNA methylation during cell fate decisions","volume":"22","author":"Parry","year":"2021","journal-title":"Nat Rev Genet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-022-00468-7","article-title":"Histone post-translational modifications - cause and consequence of genome function","volume":"23","author":"Mill\u00e1n-Zambrano","year":"2022","journal-title":"Nat Rev Genet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-023-00645-2","article-title":"RNA modifications in physiology and disease: towards clinical applications","volume":"25","author":"Delaunay","year":"2024","journal-title":"Nat Rev Genet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-023-00683-y","article-title":"Energy-driven genome regulation by ATP-dependent chromatin remodellers","volume":"25","author":"Eustermann","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1782","article-title":"Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116958","article-title":"Inhibition of DNMTs increases neoantigen-reactive T-cell toxicity against microsatellite-stable colorectal cancer in combination with radiotherapy","volume":"177","author":"Huang","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0705-y","article-title":"Design of amidobenzimidazole STING receptor agonists with systemic activity","volume":"564","author":"Ramanjulu","year":"2018","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004978","article-title":"RSV-induced H3K4 demethylase KDM5B leads to regulation of dendritic cell-derived innate cytokines and exacerbates pathogenesis in vivo","volume":"11","author":"Ptaschinski","year":"2015","journal-title":"PloS Pathog"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.1038\/ncomms7920","article-title":"A dominant role for the methyl-CpG-binding protein Mbd2 in controlling Th2 induction by dendritic cells","volume":"6","author":"Cook","year":"2015","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00975-5","article-title":"Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation","volume":"22","author":"Abdel-Hakeem","year":"2021","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00979-1","article-title":"Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans","volume":"22","author":"Yates","year":"2021","journal-title":"Nat Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.02.003","article-title":"Cancer epigenetics, tumor immunity, and immunotherapy","volume":"6","author":"Cao","year":"2020","journal-title":"Trends Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107271","article-title":"Dual inhibitors of DNMT and HDAC remodels the immune microenvironment of colorectal cancer and enhances the efficacy of anti-PD-L1 therapy","volume":"206","author":"Yang","year":"2024","journal-title":"Pharmacol Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810677","article-title":"Chidamide plus tyrosine kinase inhibitor remodel the tumor immune microenvironment and reduce tumor progression when combined with immune checkpoint inhibitor in na\u00efve and anti-PD-1 resistant CT26-bearing mice","volume":"23","author":"Chen","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024487","article-title":"Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma","volume":"144","author":"Nie","year":"2024","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1905769\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:26:59Z","timestamp":1788841619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1905769\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":32,"alternative-id":["10.3389\/fonc.2026.1905769"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1905769","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1905769"}}